Human growth hormone

Human Growth Hormone-Releasing Factor TFA, also known as Growth Hormone-Releasing Factor Human TFA, is a hypothalamic polypeptide that promotes the production and release of growth hormone (GH) through its interaction with the Growth Hormone-Releasing Hormone Receptor (GHRHR) on anterior pituitary cells [1].

Human growth hormone-releasing factor stimulates GH production and release by binding to the GHRH Receptor (GHRHR) on cells in the anterior pituitary.Growth hormone-releasing hormone is a hormone produced in the hypothalamus. The main role of growth hormo

Human growth hormone-releasing factor acetate is a hypothalamic polypeptide and stimulates GH production and release by binding to the GHRH Receptor (GHRHR) on cells in the anterior pituitary[1].

TM-N1324 is a GPR39 agonist. TM-N1324 activates human GPR39 with high efficacy and potencies of 280 nM and 9 nM in the absence and presence of Zn2+, respectively. TM-N1324 has similar potencies to murine GPR39 with EC50s of 180 nM and 5 nM, respectively.

FSH receptor antagonist 1 (compound 10) is a potent antagonist of the G(s) protein-coupled human follicle-stimulating hormone (FSH) receptor. It exhibits an IC50 value of 28 nM in cell lines expressing the human FSH receptor. This compound significantly inhibits follicle growth and ovulation in in vitro mouse models.

GHSR-1a agonist-1 (Compound 4b) is an orally active agonist of the human growth hormone secretagogue receptor 1a (GHSR-1a) with an EC50 of 0.49 nM. It effectively stimulates the release of endogenous growth hormone by activating GHSR-1a. Doses as low as 0.1 mg/kg (administered orally) can increase body weight and length in 4-week-old rats. GHSR-1a agonist-1 is applicable in research on pediatric growth and developmental delays.

Somatotropin (6-13) is a growth hormone.

1. Gitogenin, tigogenin, and solasodine are novel selective inhibitors of UGT1A4, and do not inhibit the activities of major human CYP isoforms. 2. Gitogenin and (25S)-5α-furastan-3β, 22, 26-triol are the inhibitors of enzyme α-glucosidase with IC50 value

TTA-P1 is a highly potent compound that effectively inhibits human T-type calcium channels, which are involved in various physiological processes such as neuronal burst firing, hormone secretion, and cell growth. With its unique state-independent properties, TTA-P1 holds promising potential for advancing research on absence epilepsy [1].

IRC-083927 HCl is novel and potent microtubule inhibitor with potential anticancer activity. IRC-083927 inhibits the tubulin polymerization by a binding to the colchicine site. IRC-083927 inhibits in vitro cell growth of human cancer cell lines in the low nanomolar range. More interesting, it remains highly active against cell lines resistant to microtubule-interacting agents (taxanes, Vinca alkaloids, or epothilones). Chronic oral treatment with IRC-083927 (5 mg/kg) inhibits the growth of two human tumor xenografts in nude mice (C33-A, human cervical cancer and MDA-MB-231, human hormone-independent breast cancer). Together, the antitumor effects induced by IRC-083927 on tumor models resistant to tubulin agents support further investigations to fully evaluate its potential for the treatment of advanced cancers, particularly those resistant to current clinically available drugs.

Mecasermin (Human IGF-I; FK 780), a recombinant form of human insulin-like growth factor I (IGF-I), is promising for investigating growth failure attributed to growth hormone (GH) insensitivity due to defects in GH receptors or the presence of GH-inhibiting antibodies [1].

[His1,Nle27] GHRF (1-32), amide, human is a synthetic analog of the growth hormone-releasing hormone (GHRH) with enhanced affinity for the growth hormone-releasing hormone receptor (GHRHR) [1].

pTH (1-37) (human), a fragment of parathyroid hormone (PTH), promotes cAMP formation and enhances alkaline phosphatase activity. Additionally, it fosters growth, elevates bone calcium content, and augments bone mineral density (BMD) in uremic animals. This compound shows promise for osteoporosis research [1] [2] [3].

Menotropin (Human Menopausal Gonadotropin) is a hormone discovered in the urine of postmenopausal women, possessing dual activity as follicle-stimulating hormone (FSH) and luteinizing hormone (LH). It promotes follicular growth and development, as well as the secretion of gonadal steroid hormones.

Acetyl-(D-Arg2)-GRF (1-29) amide (human) acts as a GRF antagonist and inhibits GH secretion, making it useful in endocrine research [1].

AOD9604 acetate(221231-10-3 free base) is a potential anti-obesity peptide based on the human growth hormone.

LEAP-2 (Human liver expressed antimicrobial peptide-2) is an antimicrobial peptide and an endogenous competitive antagonist of growth hormone-releasing peptide, as well as a reverse agonist of constitutive GHS-R1a activity, used for research on obesity and other metabolic diseases.

LEAP-2 acetate (Human liver expressed antimicrobial peptide-2) is an endogenous antagonist of the ghrelin receptor GHS-R1a with an IC50 of 6.0 nM, suppressing the orexigenic effects of ghrelin, attenuating ghrelin-induced growth hormone release, reducing basal food intake. LEAP-2 acetateexhibit direct antimicrobial activity against model microorganisms, thereby serving as a multifunctional peptide for mechanistic studies of obesity, metabolism, and infection biology.

(D-Ala2)-GRF (1-29) amide (human) is a potent superagonist of Growth Hormone-Releasing Factor (GRF), exhibiting approximately 50-fold higher GH-releasing activity than GRF (1-29) in both pigs and rats [1].

S1H, a synthetic peptide mimetic of human growth hormone amino acids 36-51, acts as an antagonist to the growth hormone receptor. It forms an α-helical structure in solution and inhibits STAT5 phosphorylation triggered by human growth hormone in SK-MEL-28 and MALME-3M melanoma cell lines, as well as prolactin in IM-9 B cell lymphocytes, at concentrations of 100 and 200 nM.

Inpegsomatropin is a long-acting recombinant human growth hormone that has been pegylated.

Gitogenin (Standard) is a reference standard for research and analysis in studies involving Gitogenin. 1. Gitogenin, tigogenin, and solasodine are novel selective inhibitors of UGT1A4, and do not inhibit the activities of major human CYP isoforms. 2. Gitogenin and (25S)-5α-furastan-3β, 22, 26-triol are the inhibitors of enzyme α-glucosidase with IC50 values of 37.2±0.18 and 33.5±0.22 uM, respectively.3. Gitogenin shows moderate stimulation of release activity on growth hormone from rat pituitary cells.

GLP-2(1-33) (human) is an enteroendocrine hormone that stimulates intestinal epithelium growth.

Somatostatin, also known as growth hormone-inhibiting hormone, is a naturally-occurring peptide hormone of 14 or 28 amino acid residues that regulates the endocrine system. It is secreted by the D cells of the islets to inhibit the release of insulin and